Abstract
Linezolid is commonly used for the treatment of drug-resistant Gram-positive bacterial infection. This study aimed to evaluate the efficacy and safety of linezolid in treating Gram-positive bacterial infection in the elderly from January 2010 to December 2012. Total 40 elderly patients (>60 years old) with Gram-positive bacterial infection were treated with linezolid and their demographic and clinical data were collected and analyzed. Among the 40 patients, 31 patients (77.5 %) were cured. Linezolid caused little adverse effects on liver and renal function. The main adverse effect was thrombocytopenia and its incidence was significantly associated with baseline platelet count and the duration of treatment (P < 0.05). Logistic regression analysis showed that the baseline platelet count <200 × 106/mL, but not the age, the sex, the length of hospital stay, baseline levels of hemoglobin, alanine aminotransferase, or creatinine clearance rate was significantly associated with linezolid-induced thrombocytopenia. In conclusion, linezolid is effective to cure Gram-positive bacterial infection in the elderly and causes little adverse effects on liver and renal function. Timely monitoring of baseline platelet count may be helpful to guide the use of linezolid to avoid the occurrence of thrombocytopenia.
Similar content being viewed by others
References
Goud R, Gupta S, Neogi U, Agarwal D, Naidu K, Chalannavar R, Subhaschandra G (2011) Community prevalence of methicillin and vancomycin resistant Staphylococcus aureus in and around Bangalore, southern India. Rev Soc Bras Med Trop 44:309–312
Yamaguchi T, Nakamura I, Chiba K, Matsumoto T (2012) Epidemiological and microbiological analysis of community-associated methicillin-resistant Staphylococcus aureus strains isolated from a Japanese hospital. Jpn J Infect Dis 65:175–178
Manfredi R, Sabbatani S (2010) Novel pharmaceutical molecules against emerging resistant gram-positive cocci. Braz J Infect Dis 14:96–108
Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ (2003) Linezolid for the treatment of multidrugresistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36:159–168
Aslan S, Citak EC, Yis R, Degirmenci S, Arman D (2012) Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey. Indian J Microbiol 52:203–208
Moellering RC (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135–142
Diekema DJ, Jones RN (2001) Oxazolidinone antibiotics. Lancet 358:1975–1982
Hiraki Y, Tsuji Y, Hiraike M, Misumi N, Matsumoto K, Morita K, Kamimura H, Karube Y (2012) Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 44:60–64
Gould FK. (2011) Linezolid: safety and efficacy in special populations. J Antimicrob Chemother 66 Suppl 4:iv 3–6
Thati V, Shivannavar CT, Gaddad SM (2011) Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad. Indian J Med Res 134:704–708
Shen T, Wu L, Geng L, Wei Z, Zheng S (2011) Successful treatment of pulmonary Nocardia farcinica infection with linezolid: case report and literature review. Braz J Infect Dis 15:486–489
Gerson SL, Kaplan SL, Bruss JB et al (2002) Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46:2723–2726
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, ZY., Zhao, XQ., Shan, BZ. et al. Efficacy and Safety of Linezolid in Treating Gram-Positive Bacterial Infection in the Elderly: A Retrospective Study. Indian J Microbiol 54, 104–107 (2014). https://doi.org/10.1007/s12088-013-0422-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12088-013-0422-z